bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; and TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BLUE
CUSIPN/A
Phone339-499-9300
Debt
Debt-to-Equity RatioN/A
Current Ratio10.80
Quick Ratio10.80
Price-To-Earnings
Trailing P/E Ratio-23.75
Forward P/E Ratio-19.38
P/E GrowthN/A
Sales & Book Value
Annual Sales$35.43 million
Price / Sales259.02
Cash FlowN/A
Price / CashN/A
Book Value$33.11 per share
Price / Book5.53
Profitability
EPS (Most Recent Fiscal Year)($7.71)
Net Income$-335,640,000.00
Net Margins-857.55%
Return on Equity-27.61%
Return on Assets-23.05%
Miscellaneous
Employees479
Outstanding Shares50,120,000
bluebird bio (NASDAQ:BLUE) Frequently Asked Questions
What is bluebird bio's stock symbol?
bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."
How were bluebird bio's earnings last quarter?
bluebird bio Inc (NASDAQ:BLUE) released its quarterly earnings results on Monday, May, 7th. The biotechnology company reported ($2.31) earnings per share for the quarter, missing analysts' consensus estimates of ($2.01) by $0.30. The biotechnology company earned $15.96 million during the quarter, compared to analyst estimates of $5.85 million. bluebird bio had a negative net margin of 857.55% and a negative return on equity of 27.61%. The firm's quarterly revenue was up 133.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.68) earnings per share. View bluebird bio's Earnings History.
When is bluebird bio's next earnings date?
What price target have analysts set for BLUE?
23 equities research analysts have issued 12 month price objectives for bluebird bio's stock. Their forecasts range from $122.00 to $250.00. On average, they anticipate bluebird bio's share price to reach $213.4737 in the next twelve months. View Analyst Ratings for bluebird bio.
What are Wall Street analysts saying about bluebird bio stock?
Here are some recent quotes from research analysts about bluebird bio stock:
- 1. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (3/20/2018)
- 2. Maxim Group analysts commented, "bluebird reported YE-2017 with $22M in revenue (collaborative/licensing revenue) and a net loss of $336M. Operating expenses have increased as clinical programs advance to later stages of development. The company ended the period with $1.6B in cash, sufficient runway into 2021 at the current burn rate." (2/22/2018)
- 3. Cantor Fitzgerald analysts commented, "Lining Up for Three Marketing Applications. bluebird plans to file for European approval of LentiGlobin in transfusion-dependent b-thalassemia (non-b0/b0) in 2H18, followed by bb2121 in relapsed/refractory multiple myeloma and Lenti-D in cerebral adrenoleukodystrophy in 2019. As a reminder, bb2121 is being investigated in a Phase 3 study, KarMMa, which is being conducted by bluebird’s bb2121 development partner, Celgene (CELG – Neutral, covered by Mara Goldstein)." (2/21/2018)
- 4. Morgan Stanley analysts commented, "excitement." But now may be a time for investors to turn cautious, at least according to analysts at Morgan Stanley. The firm's Matthew Harrison downgraded Bluebird's stock rating from Equal Weight to Underweight with an unchanged $105 price target.Heading into the end of 2017 there are underappreciated risks that the Street may be ignoring, Harrison commented. Specifically, data related to LentiGlobin sickle cell data is unlikely to show any significant improvement in hemoglobin production that will be good enough to "increase investor confidence" in its sickle cell gene therapy."Based on prior data, our premise is that to improve hemoglobin production in sickle cell patients, the correlation between drug-product vector copy number (DP VCN) and peripheral VCN (pVCN) needs to increase substantially," the analyst explained. "We do not believe the evidence supports current investor optimism that this can be solved by ASH." (10/2/2017)
Who are some of bluebird bio's key competitors?
Some companies that are related to bluebird bio include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Crispr Therapeutics (CRSP), argenx (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA) and Repligen (RGEN).
Who are bluebird bio's key executives?
bluebird bio's management team includes the folowing people:
- Mr. Nick Leschly, Pres, CEO & Director (Age 45)
- Mr. Jeffrey T. Walsh, Chief Financial & Strategy Officer and Treasurer (Age 52)
- Ms. Susanna Gatti High, Chief Operating Officer (Age 50)
- Dr. Philip D. Gregory D. Phil., Chief Scientific Officer (Age 47)
- Dr. David M. Davidson M.D., Chief Medical Officer (Age 54)
Has bluebird bio been receiving favorable news coverage?
Headlines about BLUE stock have been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. bluebird bio earned a media sentiment score of 0.19 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 46.59 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are bluebird bio's major shareholders?
bluebird bio's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (10.06%), BlackRock Inc. (7.72%), OppenheimerFunds Inc. (1.54%), Northern Trust Corp (1.18%), Victory Capital Management Inc. (1.11%) and Franklin Resources Inc. (0.76%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Institutional Ownership Trends for bluebird bio.
Which institutional investors are selling bluebird bio stock?
BLUE stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., OppenheimerFunds Inc., Baillie Gifford & Co., Victory Capital Management Inc., Neuberger Berman Group LLC, Lord Abbett & CO. LLC, Point72 Asset Management L.P. and Artal Group S.A.. Company insiders that have sold bluebird bio company stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Insider Buying and Selling for bluebird bio.
Which institutional investors are buying bluebird bio stock?
BLUE stock was bought by a variety of institutional investors in the last quarter, including Kayne Anderson Rudnick Investment Management LLC, Menora Mivtachim Holdings LTD., Amundi Pioneer Asset Management Inc., BlackRock Inc., Schwab Charles Investment Management Inc., UBS Group AG, GSA Capital Partners LLP and Mackay Shields LLC. View Insider Buying and Selling for bluebird bio.
How do I buy shares of bluebird bio?
Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is bluebird bio's stock price today?
One share of BLUE stock can currently be purchased for approximately $183.10.
How big of a company is bluebird bio?
bluebird bio has a market capitalization of $8.85 billion and generates $35.43 million in revenue each year. The biotechnology company earns $-335,640,000.00 in net income (profit) each year or ($7.71) on an earnings per share basis. bluebird bio employs 479 workers across the globe.
How can I contact bluebird bio?
bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]
MarketBeat Community Rating for bluebird bio (BLUE)
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe BLUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLUE will underperform the S&P 500 over the long term. You may vote once every thirty days.
